Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + sacituzumab tirumotecan + toripalimab for kidney-sparing treatment of high-risk UTUC
ChiCTR2600126555Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and toripalimab in upper tract urothelial carcinoma (UTUC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Kidney disease-free survival at 12 months (KIDFS). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantoripalimab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on ChiCTR2600126555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126555.